Despite Setbacks in Court, California’s Ban on Pharmaceutical Pay-For-Deals Could Still Recover
Posted 03/24/22
For two decades, antitrust enforcers have been fighting so-called “reverse-payment” or “pay-for-delay” agreements under which pharmaceutical patent-holders pay the allegedly infringing, lower-cost generic competition to stay off the market. California has taken a unique legislative approach, passing Assembly Bill 824 (“AB 824”) to address skyrocketing prescription drug costs by subjecting pay-for-delay...